CareDx (CDNA) Receives News Sentiment Rating of 0.22

Headlines about CareDx (NASDAQ:CDNA) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CareDx earned a coverage optimism score of 0.22 on Accern’s scale. Accern also gave news coverage about the company an impact score of 47.8985126874721 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the news articles that may have impacted Accern Sentiment’s scoring:

CDNA has been the subject of several recent research reports. Zacks Investment Research raised CareDx from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research report on Monday, September 4th. ValuEngine raised CareDx from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 24th. Craig Hallum reissued a “buy” rating and issued a $10.00 price target (up from $4.00) on shares of CareDx in a research report on Monday, October 9th. Raymond James Financial, Inc. raised CareDx from a “market perform” rating to a “buy” rating and set a $6.50 price target for the company in a research report on Wednesday, September 27th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $7.00 price target (up from $3.00) on shares of CareDx in a research report on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $6.69.

Shares of CareDx (CDNA) remained flat at $$5.82 during mid-day trading on Tuesday. The company’s stock had a trading volume of 253,300 shares, compared to its average volume of 352,429. CareDx has a twelve month low of $0.76 and a twelve month high of $6.69.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.02. The business had revenue of $12.19 million for the quarter, compared to the consensus estimate of $12.05 million. CareDx had a negative return on equity of 117.32% and a negative net margin of 84.14%. The business’s revenue was down 2.3% on a year-over-year basis. analysts forecast that CareDx will post -0.89 EPS for the current year.

In related news, major shareholder Neil Gagnon bought 21,448 shares of the stock in a transaction dated Monday, August 28th. The shares were purchased at an average price of $2.77 per share, for a total transaction of $59,410.96. Following the completion of the purchase, the insider now directly owns 903,731 shares of the company’s stock, valued at $2,503,334.87. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last quarter, insiders have acquired 73,705 shares of company stock worth $224,339. Company insiders own 5.40% of the company’s stock.

TRADEMARK VIOLATION WARNING: “CareDx (CDNA) Receives News Sentiment Rating of 0.22” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.chaffeybreeze.com/2017/11/14/caredx-cdna-receives-news-sentiment-rating-of-0-22.html.

CareDx Company Profile

CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.

Insider Buying and Selling by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply